Picard Medical Split
Picard Medical announces 1-for-50 reverse stock split for NYSE American compliance.
Anonymous
Picard Medical, Inc. (NYSE American: PMI) is consolidating its shares at a steep 1-for-50 ratio in a reverse stock split aimed at keeping its listing on NYSE American, according to GlobeNewswire. Every 50 shares of common stock will become one share, sharply lifting the per-share price while leaving each stockholder's ownership percentage unchanged.
The split is set to take effect on July 31, 2026. Trading on a split-adjusted basis will begin August 3, 2026, under the same ticker symbol, PMI, but with a new CUSIP number: 71953R 207, GlobeNewswire reported.
Why Picard Medical Needs This Stock Split
Reverse stock splits are a common tool for companies facing delisting threats. Exchanges like NYSE American require stocks to trade above a minimum price threshold. When a share price falls too low, a company can consolidate shares to push the price back up. Picard Medical's 1-for-50 ratio is among the most aggressive splits possible, signaling the stock had fallen to very low levels.
The company's Board of Directors approved the move following a stockholder vote, according to Yahoo Finance. Stockholder approval was required before the board could act, suggesting the company went through a formal proxy process to get it done.
How the Split Works for Existing Shareholders
Under the 1-for-50 split, a shareholder who owns 500 shares will end up with 10 shares after the effective date. The total value of their position stays the same on paper. Only the number of shares and the price per share change, according to GlobeNewswire.
Continental Stock Transfer and Trust Company, Picard Medical's transfer agent, will act as the exchange agent for the split process. The company will keep trading under the PMI ticker on NYSE American. The new CUSIP number, 71953R 207, will identify the post-split shares, GlobeNewswire noted.
Picard Medical and Its Heart Device Subsidiary SynCardia
Picard Medical is the parent company of SynCardia Systems LLC, according to QuiverQuant. SynCardia makes the Total Artificial Heart, a device implanted in patients with end-stage heart failure. It is the only FDA-approved total artificial heart and has been used in more than 2,000 patients worldwide.
The compliance issue reflects broader financial pressures at the company, not problems with SynCardia's core medical product. Maintaining the NYSE American listing keeps the stock accessible to a wider range of investors and preserves the company's credibility in the public markets.
Key Dates Investors Need to Watch
The reverse stock split becomes effective on July 31, 2026. Shares will start trading on a split-adjusted basis on August 3, 2026, according to TradingView. Investors who hold shares before the effective date will see their share count reduced automatically through their brokerage accounts.
No action is required from most stockholders who hold shares in brokerage accounts. Those holding physical stock certificates should contact Continental Stock Transfer and Trust Company for instructions. The PMI ticker symbol will not change, making the transition straightforward for most investors, TradingView reported.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
5
Articles
5
Reach
5
A
AnonymousAuthor